| JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells KA Heslop, A Rovini, EG Hunt, D Fang, ME Morris, CF Christie, MB Gooz, ... Biochemical pharmacology 171, 113728, 2020 | 72 | 2020 |
| Bcl-2—Enhanced Efficacy of Microtubule-Targeting Chemotherapy through Bim Overexpression: Implications for Cancer Treatment A Savry, M Carre, R Berges, A Rovini, I Pobel, C Chacon, D Braguer, ... Neoplasia 15 (1), 49-IN17, 2013 | 61 | 2013 |
| Olesoxime prevents microtubule-targeting drug neurotoxicity: selective preservation of EB comets in differentiated neuronal cells A Rovini, M Carré, T Bordet, RM Pruss, D Braguer Biochemical pharmacology 80 (6), 884-894, 2010 | 53 | 2010 |
| Molecular mechanism of olesoxime-mediated neuroprotection through targeting α-synuclein interaction with mitochondrial VDAC A Rovini, PA Gurnev, A Beilina, M Queralt-Martín, W Rosencrans, ... Cellular and Molecular Life Sciences 77 (18), 3611-3626, 2020 | 45 | 2020 |
| ROS-mediated EB1 phosphorylation through Akt/GSK3β pathway: implication in cancer cell response to microtubule-targeting agents M Le Grand, A Rovini, V Bourgarel-Rey, S Honore, S Bastonero, ... Oncotarget 5 (10), 3408, 2014 | 44 | 2014 |
| Sequence diversity of tubulin isotypes in regulation of the mitochondrial voltage-dependent anion channel TK Rostovtseva, PA Gurnev, DP Hoogerheide, A Rovini, M Sirajuddin, ... Journal of Biological Chemistry 293 (28), 10949-10962, 2018 | 43 | 2018 |
| Quantitative analysis of mitochondrial membrane potential heterogeneity in unsynchronized and synchronized cancer cells A Rovini, K Heslop, EG Hunt, ME Morris, D Fang, M Gooz, AA Gerencser, ... The FASEB Journal 35 (1), e21148, 2021 | 38 | 2021 |
| The macrophage: a key player in the pathophysiology of peripheral neuropathies Z Msheik, M El Massry, A Rovini, F Billet, A Desmoulière Journal of Neuroinflammation 19 (1), 1-18, 2022 | 34 | 2022 |
| Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status A Rovini, G Gauthier, R Bergès, A Kruczynski, D Braguer, S Honoré PLoS One 8 (6), e65694, 2013 | 34 | 2013 |
| Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content CF Christie, D Fang, EG Hunt, ME Morris, A Rovini, KA Heslop, ... The FASEB Journal 33 (7), 8186-8201, 2019 | 30 | 2019 |
| Probing membrane association of α-synuclein domains with VDAC nanopore reveals unexpected binding pattern D Jacobs, DP Hoogerheide, A Rovini, Z Jiang, JC Lee, TK Rostovtseva, ... Scientific reports 9 (1), 1-14, 2019 | 28 | 2019 |
| Mathematical model of cancer growth controled by metronomic chemotherapies N Andre, D Barbolosi, F Billy, G Chapuisat, F Hubert, E Grenier, A Rovini ESAIM: Proceedings 41, 77-94, 2013 | 25 | 2013 |
| Tubulin-VDAC interaction: molecular basis for mitochondrial dysfunction in chemotherapy-induced peripheral neuropathy A Rovini Frontiers in Physiology 10, 671, 2019 | 20 | 2019 |
| The angiotensin II type 2 receptor, a target for protection and regeneration of the peripheral nervous system? A Danigo, A Rovini, F Bessaguet, H Bouchenaki, A Bernard, F Sturtz, ... Pharmaceuticals 14 (3), 175, 2021 | 12 | 2021 |
| Lipids in regulation of the mitochondrial outer membrane permeability, bioenergetics, and metabolism TK Rostovtseva, DP Hoogerheide, A Rovini, SM Bezrukov Molecular basis for mitochondrial signaling, 185-215, 2017 | 12 | 2017 |
| DNA methylation patterns in human iPSC-derived sensory neuronal differentiation S Ankam, A Rovini, S Baheti, R Hrstka, Y Wu, K Schmidt, H Wang, ... Epigenetics 14 (9), 927-937, 2019 | 11 | 2019 |
| The Cholecystokinin Type 2 Receptor, a Pharmacological Target for Pain Management A Bernard, A Danigo, S Bourthoumieu, M Mroué, A Desmoulière, F Sturtz, ... Pharmaceuticals 14 (11), 1185, 2021 | 8 | 2021 |
| Evidences of a Direct Relationship between Cellular Fuel Supply and Ciliogenesis Regulated by Hypoxic VDAC1-ΔC M Meyenberg Cunha-de Padua, L Fabbri, M Dufies, S Lacas-Gervais, ... Cancers 12 (11), 3484, 2020 | 8 | 2020 |
| Restricting α-Synuclein Transport into Mitochondria by Inhibition of α-Synuclein-VDAC Complexation as a Potential Therapeutic Target for Parkinson’s Disease Treatment M Rajendran, M Queralt-Martín, PA Gurnev, WM Rosencrans, A Rovini, ... bioRxiv, 2022 | 4 | 2022 |
| Mitochondria and Tumor Metabolic Flexibility: Mechanisms and Therapeutic Perspectives A Rovini, KA Heslop, EN Maldonado Elsevier, 2021 | 3 | 2021 |
Sergey M. BezrukovNIHVerified email at mail.nih.gov
